| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our internationally renowned clinical microbiology laboratories offer a broad selection of tests designed for rapid identification and in-depth characterization of the causative agents of infectious diseases. We have developed and implemented culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular methods for rapid detection, identification, and characterization, as well as provision of treatment guidance for microbial pathogens.
“We're always trying to develop new methods, broader methods, faster methods, less expensive methods.”
Nancy Wengenack, Ph.D., Division of Clinical Microbiology
Our difference
The latest
William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.
In this month's "Hot Topic," Robin Patel, M.D., discusses how the use of multiplex tests may reduce the turnaround time for identifying the cause of bloodstream infections, and how this might impact antibiotic stewardship and patient outcomes.
In this month's "Hot Topic," Matthew Binnicker, Ph.D., discusses the use of multiplex panels for the diagnosis of respiratory infections and focuses on the clinical utility of these tests in the setting of upper respiratory tract infections.
The field of clinical microbiology has a long and distinguished history at Mayo Clinic. Since the early 1900s, the clinical microbiology team has played important and leading roles in advancing testing and patient care.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt discuss the range of emerging viruses and their variants that are currently in the news.
Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D. about recent outbreaks of viral infections. In this episode, Dr. Binnicker and Dr. Pritt look at the hepatitis cases in children possibly linked to adenovirus as well as the spread of Monkeypox.
Elitza Theel, Ph.D., director of the Infectious Diseases Serology Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D. about tick-borne disease testing. In this episode, Dr. Theel and Dr. Pritt look at emerging tick-borne illnesses, the tests available to detect these infections, and how to prevent them.
Recognizing Dr. Pritt’s innovative work in medical education, the Infectious Diseases Society of America is highlighting her role as an educator in its monthly series.
In this month's "Hot Topic," Elitza Theel, Ph.D., will be discussing laboratory utilization management, specifically for diagnostic testing for tick-borne diseases.
In this month’s “Hot Topic,” Nancy Wengenack, Ph.D., discusses susceptibility testing of yeast for those who are considering performing it in their laboratory, perhaps for the first time, or for those who choose to send their yeast isolates out to a reference laboratory for susceptibility testing but who want to understand how the reference laboratory generates the data that comes back on reports.
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.
Joseph Yao, M.D., explains how Mayo Clinic Laboratories’ SARS four-target test for viral respiratory disease can enhance patient care. The test detects RNA from SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus, or RSV. RSV — which poses significant risks for infants and patients with underlying health conditions — can be treated if diagnosed early.
If you need a test for COVID-19, a variety of options are now available. But how do you know which one is right for you? Use this guide from Mayo Clinic Laboratories to sort through the choices and help you decide.